ロード中...
Randomized Phase II Designs
As the use of molecularly targeted agents, which are anticipated to increase overall and progression-free survival (OS and PFS), but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such d...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3774021/ https://ncbi.nlm.nih.gov/pubmed/19276275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2031 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|